Analysts’ Updated EPS Estimates for February 10th (AAMI, ANVS, APGE, ARQT, ATR, ATRC, AVTR, AXSM, BDC, CNO)

Analysts’ updated eps estimates for Monday, February 10th:

Acadian Asset Management (NYSE:AAMI) had its sector perform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $27.00 target price on the stock.

Annovis Bio (NYSE:ANVS) had its hold rating reissued by analysts at D. Boral Capital.

Apogee Therapeutics (NASDAQ:APGE) had its buy rating reiterated by analysts at Guggenheim.

Arcutis Biotherapeutics (NASDAQ:ARQT) had its buy rating reaffirmed by analysts at Guggenheim.

AptarGroup (NYSE:ATR) had its outperform rating reissued by analysts at Raymond James. They currently have a $190.00 target price on the stock, down from their previous target price of $200.00.

AtriCure (NASDAQ:ATRC) had its market outperform rating reiterated by analysts at JMP Securities. The firm currently has a $60.00 price target on the stock.

Avantor (NYSE:AVTR) had its outperform rating reaffirmed by analysts at Raymond James. The firm currently has a $24.00 target price on the stock, down from their previous target price of $26.00.

Axsome Therapeutics (NASDAQ:AXSM) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $133.00 price target on the stock.

Belden (NYSE:BDC) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $130.00 target price on the stock.

CNO Financial Group (NYSE:CNO) had its overweight rating reissued by analysts at Piper Sandler. They currently have a $46.00 target price on the stock, up from their previous target price of $44.00.

Centessa Pharmaceuticals (NASDAQ:CNTA) had its buy rating reaffirmed by analysts at Guggenheim.

Corbus Pharmaceuticals (NASDAQ:CRBP) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $75.00 target price on the stock, down from their previous target price of $80.00.

Carriage Services (NYSE:CSV) had its outperform rating reaffirmed by analysts at Barrington Research. Barrington Research currently has a $50.00 price target on the stock.

Digital Realty Trust (NYSE:DLR) had its market outperform rating reaffirmed by analysts at JMP Securities. They currently have a $220.00 target price on the stock.

GrafTech International (NYSE:EAF) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $2.00 target price on the stock.

Eversource Energy (NYSE:ES) had its buy rating reiterated by analysts at Guggenheim.

4D Molecular Therapeutics (NASDAQ:FDMT) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $36.00 target price on the stock.

Fifth Third Bancorp (NASDAQ:FITB) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $47.00 price target on the stock.

Immix Biopharma (NASDAQ:IMMX) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $7.00 target price on the stock.

IQVIA (NYSE:IQV) had its buy rating reiterated by analysts at Truist Financial Co.. The firm currently has a $263.00 price target on the stock, up from their previous price target of $261.00.

IQVIA (NYSE:IQV) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $270.00 price target on the stock.

Karyopharm Therapeutics (NASDAQ:KPTI) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $3.00 price target on the stock.

Kilroy Realty (NYSE:KRC) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $44.00 target price on the stock.

Lumen Technologies (NYSE:LUMN) had its sector perform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $4.25 target price on the stock.

McDonald’s (NYSE:MCD) had its hold rating reissued by analysts at TD Securities. They currently have a $300.00 target price on the stock.

Mohawk Industries (NYSE:MHK) had its strong-buy rating reaffirmed by analysts at Raymond James. Raymond James currently has a $165.00 target price on the stock, down from their previous target price of $185.00.

Mach Natural Resources (NYSE:MNR) had its strong-buy rating reiterated by analysts at Raymond James. Raymond James currently has a $25.00 price target on the stock, up from their previous price target of $23.00.

MACOM Technology Solutions (NASDAQ:MTSI) had its buy rating reiterated by analysts at Benchmark Co.. The firm currently has a $160.00 price target on the stock.

Annaly Capital Management (NYSE:NLY) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $22.00 target price on the stock.

OKYO Pharma (NASDAQ:OKYO) had its buy rating reissued by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

ORIC Pharmaceuticals (NASDAQ:ORIC) had its buy rating reiterated by analysts at Guggenheim.

Palo Alto Networks (NASDAQ:PANW) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $225.00 target price on the stock.

Pfizer (NYSE:PFE) had its buy rating reaffirmed by analysts at Guggenheim. They currently have a $33.00 target price on the stock.

Pliant Therapeutics (NASDAQ:PLRX) had its hold rating reaffirmed by analysts at Canaccord Genuity Group Inc.. The firm currently has a $4.00 target price on the stock, down from their previous target price of $43.00.

Pliant Therapeutics (NASDAQ:PLRX) had its market perform rating reiterated by analysts at Oppenheimer Holdings Inc..

Praxis Precision Medicines (NASDAQ:PRAX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $150.00 target price on the stock.

Qualys (NASDAQ:QLYS) had its market perform rating reaffirmed by analysts at Northland Securities. The firm currently has a $146.00 target price on the stock, down from their previous target price of $150.00.

Qualys (NASDAQ:QLYS) had its hold rating reiterated by analysts at Needham & Company LLC.

Reinsurance Group of America (NYSE:RGA) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $245.00 target price on the stock.

Rezolute (NASDAQ:RZLT) had its buy rating reiterated by analysts at Guggenheim.

SiteOne Landscape Supply (NYSE:SITE) had its hold rating reaffirmed by analysts at Stifel Nicolaus. They currently have a $140.00 price target on the stock, down from their previous price target of $145.00.

Skyward Specialty Insurance Group (NASDAQ:SKWD) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $60.00 price target on the stock.

Semtech (NASDAQ:SMTC) had its overweight rating reiterated by analysts at Piper Sandler. Piper Sandler currently has a $55.00 price target on the stock, down from their previous price target of $75.00.

SolarWinds (NYSE:SWI) had its hold rating reaffirmed by analysts at Truist Financial Co.. Truist Financial Co. currently has a $18.50 price target on the stock, up from their previous price target of $13.00.

Tarsus Pharmaceuticals (NASDAQ:TARS) had its buy rating reaffirmed by analysts at Guggenheim.

Terreno Realty (NYSE:TRNO) had its market outperform rating reissued by analysts at JMP Securities. The firm currently has a $72.00 price target on the stock.

Tesla (NASDAQ:TSLA) had its hold rating reaffirmed by analysts at Needham & Company LLC.

Ubiquiti (NYSE:UI) had its buy rating reaffirmed by analysts at BWS Financial. BWS Financial currently has a $440.00 price target on the stock.

Viasat (NASDAQ:VSAT) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $19.00 price target on the stock.

Western Digital (NASDAQ:WDC) had its overweight rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $95.00 target price on the stock.

Xometry (NASDAQ:XMTR) had its market outperform rating reissued by analysts at JMP Securities. They currently have a $42.00 price target on the stock.

Zimmer Biomet (NYSE:ZBH) had its hold rating reissued by analysts at Truist Financial Co.. They currently have a $113.00 price target on the stock, down from their previous price target of $118.00.